Document is current

Article History

Accepted: 17 August 2024

First Online: 2 September 2024

Declarations

:

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: MS: is a member and co-chair of the Joint Task Force on Practice Parameters, serves on the editorial board of The Journal of Allergy and Clinical Immunology In Practice, is an associate editor of Annals of Allergy, Asthma & Immunology, and serves on the board of directors of the American Academy of Allergy, Asthma& Immunology (views expressed are his own).AA: reports institutional funding (Aimmune, Novartis, FARE), Advisory Board member (DBV Technologies, Novartis, Bryn, Ready, set, food, Genentech), consultation/speaker fees (ALK, Adelphi, Medscape, Innovation horizons, EPG Health, Genentech, FARE).MG: is a consultant for Aquestive; is a member of physician/medical advisory boards for DBV Technologies, Takeda, Griffols, Nutricia, Novartis, Aquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, Bryn, Genentech, and Prota; is a speaker for Genentech; is an unpaid member of the scientific advisory council for the National Peanut Board and medical advisory board of the International Food Protein Induced Enterocolitis Syndrome Association; is a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group; is the senior associate editor for the Annals of Allergy, Asthma, and Immunology, and is member of the Joint Taskforce on Allergy Practice Parameters. He has received honorarium for lectures from ImSci, Red Nucleus, Medscape, Paradigm Medical Communications, Kaplan, Food Allergy Research and Education, and multiple state/local allergy societies.